anti-secretory

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.

Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.

Lafutidine (FRG-8813) is a newly developed histamine H2-receptor antagonist that inhibits gastric acid secretion.

Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

BTM-1086 is a potent gastric secretory inhibitor and an anti-ulcer agent.

Tris(2,4-di-tert-butylphenyl)phosphate (TDTBPP) isolated from Vitex negundoL inhibits secretory phospholipase A2 (sPLA2). Tris(2,4-di-tert-butylphenyl)phosphate has anti-inflammatory activity.

SCH28080 is a reversible and K+-competitive inhibitor of gastric H+/K+-ATPase with an IC50 value of 20 nM (rabbit microsomal membrane).SCH28080 is a potent inhibitor of acid secretion in vivo with anti-ulcer activity, anti-secretory and cytoprotective activity.

Diallylmelamine is an anti-secretory agent for the stomach.

Varespladib (LY315920), a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome.

Ro 23-9358 is a potent inhibitor of secretory phospholipase A2, exhibiting anti-inflammatory properties.

Namptactivator-5 (compound C8) is a potent activator of nicotinamide phosphoribosyltransferase (NAMPT), with a KD value of 6.19 µM. This compound demonstrates cellular anti-aging effects by promoting NAD+ production in the brain and reducing markers and secretory phenotypes associated with aging. Namptactivator-5 holds potential for researching age-related diseases.

Hydroflumethiazide is an orally active thiazide diuretic that can directly stimulate the secretory function of pancreatic A cells in normal pancreas and in alloxan-induced diabetes models.

Hexocyclium metilsulfate has anti-gastric secretory effects in humans.

FIZZ-1 (32-51) (mouse), a cysteine-rich secretory protein, is primarily expressed in macrophages, bronchial epithelial, and type II alveolar epithelial cells (AEC) during allergic airway inflammation. It also demonstrates an anti-apoptotic effect on lung fibroblasts, suggesting its potential utility in allergic pneumonia research [1] [2].

ESAT6 Epitope is a known CD4+ T cell epitope within the Early Secretory Antigenic Target 6 (ESAT6), demonstrating nanoscale affinity (IC50=180 nM) for Major Histocompatibility Complex MHC class I. Additionally, ESAT6 Epitope can enhance the anti-tuberculosis cellular immunity initiated by the Bacille Calmette-Guérin vaccine.

1. Dehydroabietic acid (Dehydroabietate) (DAA) is an EBV-EA activation inhibitor. 2. DAA is a useful food-derived compound for treating obesity-related diseases, by decreasing plasma glucose, insulin levels, plasma triglyceride (TG) , and hepatic TG levels. 3. DAA derivatives displays anti-secretory and anti-pepsin effect in animal models.

Rhamnetin (Standard) is a reference standard for research and analysis in studies involving Rhamnetin. Rhamnetin (beta-Rhamnocitrin), a quercetin derivative found in Coriandrum sativum, has antioxidant and anti-inflammatory activities. Rhamnetin inhibits secretory phospholipase A2.

Dehydroabietic acid (Standard) is a reference standard for research and analysis in studies involving Dehydroabietic acid. 1. Dehydroabietic acid (Dehydroabietate) (DAA) is an EBV-EA activation inhibitor. 2. DAA is a useful food-derived compound for treating obesity-related diseases, by decreasing plasma glucose, insulin levels, plasma triglyceride (TG) , and hepatic TG levels. 3. DAA derivatives displays anti-secretory and anti-pepsin effect in animal models.

Rhamnetin (beta-Rhamnocitrin), a quercetin derivative found in Coriandrum sativum, has antioxidant and anti-inflammatory activities. Rhamnetin inhibits secretory phospholipase A2.

Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L increases the SA-β-galactosidase activity, promotes the production of senescence-associated secretory cytokines. Gypenoside L also can activate p38 and ERK MAPK pathways and NF-κB pathway to induce senescence. Gypenoside L exhibits anti-tumor and anti-inflammatory activities.

Nimbin is an anti-pyretic, can be used to treat arthritis, hypoglycaemia, peptic ulcers, anti-secretory activity, and it can also be used as an antibiotic. Nimbin requires to elicit a 50% inhibition of this steroid hydroxylase activity in the three insect